Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK

Ward, Anthony and Caro, J.J. and Getsios, D. and Ishak, K. and O'Brien, John T. and Bullock, Roger A. (2003) Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. International Journal of Geriatric Psychiatry, 18 (8). pp. 740-747. ISSN 0885-6230. (The full text of this publication is not available from this repository)

The full text of this publication is not available from this repository. (Contact us about this Publication)
Official URL
http://dx.doi.org/10.1002/gps.919

Abstract

Objective To assess the long-term health and economic impact of treating mild to moderate Alzheimer's disease (AD) with galantamine (16 mg or 24 mg per day) compared to no cholinesterase therapy in the UK

Item Type: Article
Additional information: IN FILE
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Divisions: Faculties > Science Technology and Medical Studies > Kent Institute of Medicine and Health Sciences (KIMHS)
Depositing User: M.P. Stone
Date Deposited: 12 Sep 2008 13:45
Last Modified: 04 Jun 2014 14:17
Resource URI: http://kar.kent.ac.uk/id/eprint/12305 (The current URI for this page, for reference purposes)
  • Depositors only (login required):